{
  "guideline": {
    "id": "PA166104999",
    "name": "Annotation of CPIC Guideline for imipramine and CYP2C19, CYP2D6",
    "source": "CPIC",
    "version": 47,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166104999",
    "relatedChemicals": [
      {
        "id": "PA449969",
        "name": "imipramine",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA124",
        "name": "cytochrome P450 family 2 subfamily C member 19",
        "symbol": "CYP2C19"
      },
      {
        "id": "PA128",
        "name": "cytochrome P450 family 2 subfamily D member 6",
        "symbol": "CYP2D6"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166298118",
      "name": "Recommendation PA166298118",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060720,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "n/a",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298065",
      "name": "Recommendation PA166298065",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060667,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298105",
      "name": "Recommendation PA166298105",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060707,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.5",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298052",
      "name": "Recommendation PA166298052",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060654,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "1.0",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298162",
      "name": "Recommendation PA166298162",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060764,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298043",
      "name": "Recommendation PA166298043",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060645,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.75",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298175",
      "name": "Recommendation PA166298175",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060777,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.25",
        "CYP2C19": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297980",
      "name": "Recommendation PA166297980",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060582,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "1.0",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298109",
      "name": "Recommendation PA166298109",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060711,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.75",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298078",
      "name": "Recommendation PA166298078",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060680,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "1.0",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301422",
      "name": "Recommendation Annotation PA166301422",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452095761,
        "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x≥3</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x≥3</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x≥3</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x≥3</strong> or <strong>*2x2 versus *2x≥3</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x≥3</td>\n<td>Increased</td>\n<td>≥3</td>\n<td></td>\n<td></td>\n<td>≥3</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "xN combinations",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298030",
      "name": "Recommendation PA166298030",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060632,
        "html": "<p>Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.5",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298140",
      "name": "Recommendation PA166298140",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060742,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.0",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298017",
      "name": "Recommendation PA166298017",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060619,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298061",
      "name": "Recommendation PA166298061",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060663,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "3.0",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298101",
      "name": "Recommendation PA166298101",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060703,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.5",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298149",
      "name": "Recommendation PA166298149",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060751,
        "html": "<p>Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.75",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298004",
      "name": "Recommendation PA166298004",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060606,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.75",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298096",
      "name": "Recommendation PA166298096",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060698,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297993",
      "name": "Recommendation PA166297993",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060595,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298114",
      "name": "Recommendation PA166298114",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060716,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297997",
      "name": "Recommendation PA166297997",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060599,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298087",
      "name": "Recommendation PA166298087",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060689,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "3.0",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298171",
      "name": "Recommendation PA166298171",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060773,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.25",
        "CYP2C19": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298008",
      "name": "Recommendation PA166298008",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060610,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.75",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297984",
      "name": "Recommendation PA166297984",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060586,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.75",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298127",
      "name": "Recommendation PA166298127",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060729,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.5",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298074",
      "name": "Recommendation PA166298074",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060676,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.0",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298184",
      "name": "Recommendation PA166298184",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060786,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298025",
      "name": "Recommendation PA166298025",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060627,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.25",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298157",
      "name": "Recommendation PA166298157",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060759,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297998",
      "name": "Recommendation PA166297998",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060600,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298012",
      "name": "Recommendation PA166298012",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060614,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "3.0",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298122",
      "name": "Recommendation PA166298122",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060724,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.25",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297985",
      "name": "Recommendation PA166297985",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060587,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.0",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298003",
      "name": "Recommendation PA166298003",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060605,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.5",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297989",
      "name": "Recommendation PA166297989",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060591,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.75",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298095",
      "name": "Recommendation PA166298095",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060697,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298135",
      "name": "Recommendation PA166298135",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060737,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.75",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298038",
      "name": "Recommendation PA166298038",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060640,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "4.0",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297976",
      "name": "Recommendation PA166297976",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060578,
        "html": "<p>Avoid imipramine use. If a imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.0",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298082",
      "name": "Recommendation PA166298082",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060684,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.75",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298100",
      "name": "Recommendation PA166298100",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060702,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.25",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298069",
      "name": "Recommendation PA166298069",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060671,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298021",
      "name": "Recommendation PA166298021",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060623,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298153",
      "name": "Recommendation PA166298153",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060755,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "3.0",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298056",
      "name": "Recommendation PA166298056",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060658,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.75",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301404",
      "name": "Recommendation Annotation PA166301404",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452095743,
        "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x≥3</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x≥3</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x≥3</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x≥3</strong> or <strong>*2x2 versus *2x≥3</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x≥3</td>\n<td>Increased</td>\n<td>≥3</td>\n<td></td>\n<td></td>\n<td>≥3</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "xN combinations",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298166",
      "name": "Recommendation PA166298166",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060768,
        "html": "<p>Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.0",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298047",
      "name": "Recommendation PA166298047",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060649,
        "html": "<p>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "No Result",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298091",
      "name": "Recommendation PA166298091",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060693,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298131",
      "name": "Recommendation PA166298131",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060733,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298179",
      "name": "Recommendation PA166298179",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060781,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298034",
      "name": "Recommendation PA166298034",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060636,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.5",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298144",
      "name": "Recommendation PA166298144",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060746,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.75",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298053",
      "name": "Recommendation PA166298053",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060655,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.5",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298185",
      "name": "Recommendation PA166298185",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060787,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297990",
      "name": "Recommendation PA166297990",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060592,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "4.0",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298119",
      "name": "Recommendation PA166298119",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060721,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "No Result",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298088",
      "name": "Recommendation PA166298088",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060690,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.75",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298040",
      "name": "Recommendation PA166298040",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060642,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298150",
      "name": "Recommendation PA166298150",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060752,
        "html": "<p>Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.0",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298009",
      "name": "Recommendation PA166298009",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060611,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.0",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298106",
      "name": "Recommendation PA166298106",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060708,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.75",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298079",
      "name": "Recommendation PA166298079",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060681,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.75",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298031",
      "name": "Recommendation PA166298031",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060633,
        "html": "<p>Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.75",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298163",
      "name": "Recommendation PA166298163",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060765,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298066",
      "name": "Recommendation PA166298066",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060668,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298176",
      "name": "Recommendation PA166298176",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060778,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.5",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298005",
      "name": "Recommendation PA166298005",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060607,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "1.0",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301421",
      "name": "Recommendation Annotation PA166301421",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452095760,
        "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x≥3</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x≥3</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x≥3</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x≥3</strong> or <strong>*2x2 versus *2x≥3</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x≥3</td>\n<td>Increased</td>\n<td>≥3</td>\n<td></td>\n<td></td>\n<td>≥3</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "xN combinations",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298097",
      "name": "Recommendation PA166298097",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060699,
        "html": "<p>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "n/a",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298181",
      "name": "Recommendation PA166298181",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060783,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298137",
      "name": "Recommendation PA166298137",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060739,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297994",
      "name": "Recommendation PA166297994",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060596,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298084",
      "name": "Recommendation PA166298084",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060686,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.25",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297981",
      "name": "Recommendation PA166297981",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060583,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.25",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298102",
      "name": "Recommendation PA166298102",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060704,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.75",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298075",
      "name": "Recommendation PA166298075",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060677,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.25",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298115",
      "name": "Recommendation PA166298115",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060717,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.75",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298018",
      "name": "Recommendation PA166298018",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060620,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298062",
      "name": "Recommendation PA166298062",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060664,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.75",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298172",
      "name": "Recommendation PA166298172",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060774,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.5",
        "CYP2C19": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298128",
      "name": "Recommendation PA166298128",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060730,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "3.0",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297999",
      "name": "Recommendation PA166297999",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060601,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "n/a",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298013",
      "name": "Recommendation PA166298013",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060615,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.75",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298145",
      "name": "Recommendation PA166298145",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060747,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "1.0",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298048",
      "name": "Recommendation PA166298048",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060650,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.0",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297986",
      "name": "Recommendation PA166297986",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060588,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.25",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298000",
      "name": "Recommendation PA166298000",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060602,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "No Result",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298092",
      "name": "Recommendation PA166298092",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060694,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298158",
      "name": "Recommendation PA166298158",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060760,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298110",
      "name": "Recommendation PA166298110",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060712,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "4.0",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297977",
      "name": "Recommendation PA166297977",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060579,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.25",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298039",
      "name": "Recommendation PA166298039",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060641,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298083",
      "name": "Recommendation PA166298083",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060685,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.0",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298123",
      "name": "Recommendation PA166298123",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060725,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.5",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298026",
      "name": "Recommendation PA166298026",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060628,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.5",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298070",
      "name": "Recommendation PA166298070",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060672,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298180",
      "name": "Recommendation PA166298180",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060782,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298136",
      "name": "Recommendation PA166298136",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060738,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298057",
      "name": "Recommendation PA166298057",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060659,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.0",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298141",
      "name": "Recommendation PA166298141",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060743,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.25",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298044",
      "name": "Recommendation PA166298044",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060646,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298154",
      "name": "Recommendation PA166298154",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060756,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.75",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298035",
      "name": "Recommendation PA166298035",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060637,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.25",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301403",
      "name": "Recommendation Annotation PA166301403",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452095742,
        "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x≥3</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x≥3</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x≥3</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x≥3</strong> or <strong>*2x2 versus *2x≥3</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x≥3</td>\n<td>Increased</td>\n<td>≥3</td>\n<td></td>\n<td></td>\n<td>≥3</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "xN combinations",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298167",
      "name": "Recommendation PA166298167",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060769,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.25",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298022",
      "name": "Recommendation PA166298022",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060624,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "n/a",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298132",
      "name": "Recommendation PA166298132",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060734,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298089",
      "name": "Recommendation PA166298089",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060691,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "4.0",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298041",
      "name": "Recommendation PA166298041",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060643,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298173",
      "name": "Recommendation PA166298173",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060775,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.75",
        "CYP2C19": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298107",
      "name": "Recommendation PA166298107",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060709,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.0",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301424",
      "name": "Recommendation Annotation PA166301424",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452095763,
        "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x≥3</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x≥3</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x≥3</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x≥3</strong> or <strong>*2x2 versus *2x≥3</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x≥3</td>\n<td>Increased</td>\n<td>≥3</td>\n<td></td>\n<td></td>\n<td>≥3</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "xN combinations",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298076",
      "name": "Recommendation PA166298076",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060678,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.5",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298186",
      "name": "Recommendation PA166298186",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060788,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "n/a",
        "CYP2C19": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298067",
      "name": "Recommendation PA166298067",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060669,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298151",
      "name": "Recommendation PA166298151",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060753,
        "html": "<p>Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.25",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298054",
      "name": "Recommendation PA166298054",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060656,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.25",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298164",
      "name": "Recommendation PA166298164",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060766,
        "html": "<p>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "n/a",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297991",
      "name": "Recommendation PA166297991",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060593,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298085",
      "name": "Recommendation PA166298085",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060687,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.5",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298125",
      "name": "Recommendation PA166298125",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060727,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "1.0",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298028",
      "name": "Recommendation PA166298028",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060630,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "1.0",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298072",
      "name": "Recommendation PA166298072",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060674,
        "html": "<p>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "No Result",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298182",
      "name": "Recommendation PA166298182",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060784,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298138",
      "name": "Recommendation PA166298138",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060740,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "n/a",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298063",
      "name": "Recommendation PA166298063",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060665,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "4.0",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298103",
      "name": "Recommendation PA166298103",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060705,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "1.0",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298129",
      "name": "Recommendation PA166298129",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060731,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.75",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298006",
      "name": "Recommendation PA166298006",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060608,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.25",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298098",
      "name": "Recommendation PA166298098",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060700,
        "html": "<p>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "No Result",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298050",
      "name": "Recommendation PA166298050",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060652,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.5",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298160",
      "name": "Recommendation PA166298160",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060762,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298019",
      "name": "Recommendation PA166298019",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060621,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.75",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297995",
      "name": "Recommendation PA166297995",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060597,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298116",
      "name": "Recommendation PA166298116",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060718,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298049",
      "name": "Recommendation PA166298049",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060651,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.25",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298001",
      "name": "Recommendation PA166298001",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060603,
        "html": "<p>Avoid imipramine use. If a imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.0",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297987",
      "name": "Recommendation PA166297987",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060589,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.5",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298093",
      "name": "Recommendation PA166298093",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060695,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298133",
      "name": "Recommendation PA166298133",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060735,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298036",
      "name": "Recommendation PA166298036",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060638,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "3.0",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298080",
      "name": "Recommendation PA166298080",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060682,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.25",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298146",
      "name": "Recommendation PA166298146",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060748,
        "html": "<p>Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.25",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298027",
      "name": "Recommendation PA166298027",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060629,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.75",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298071",
      "name": "Recommendation PA166298071",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060673,
        "html": "<p>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "n/a",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298159",
      "name": "Recommendation PA166298159",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060761,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298111",
      "name": "Recommendation PA166298111",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060713,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298014",
      "name": "Recommendation PA166298014",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060616,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "4.0",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298124",
      "name": "Recommendation PA166298124",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060726,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.75",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298045",
      "name": "Recommendation PA166298045",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060647,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298177",
      "name": "Recommendation PA166298177",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060779,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "3.0",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297978",
      "name": "Recommendation PA166297978",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060580,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.5",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298032",
      "name": "Recommendation PA166298032",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060634,
        "html": "<p>Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.0",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298142",
      "name": "Recommendation PA166298142",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060744,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.75",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298023",
      "name": "Recommendation PA166298023",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060625,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "No Result",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301402",
      "name": "Recommendation Annotation PA166301402",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452095741,
        "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x≥3</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x≥3</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x≥3</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x≥3</strong> or <strong>*2x2 versus *2x≥3</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x≥3</td>\n<td>Increased</td>\n<td>≥3</td>\n<td></td>\n<td></td>\n<td>≥3</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "xN combinations",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298058",
      "name": "Recommendation PA166298058",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060660,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.25",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298010",
      "name": "Recommendation PA166298010",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060612,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.25",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298120",
      "name": "Recommendation PA166298120",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060722,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.0",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298168",
      "name": "Recommendation PA166298168",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060770,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.5",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301401",
      "name": "Recommendation Annotation PA166301401",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452095740,
        "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x≥3</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x≥3</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x≥3</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x≥3</strong> or <strong>*2x2 versus *2x≥3</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x≥3</td>\n<td>Increased</td>\n<td>≥3</td>\n<td></td>\n<td></td>\n<td>≥3</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "xN combinations",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298077",
      "name": "Recommendation PA166298077",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060679,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.75",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298161",
      "name": "Recommendation PA166298161",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060763,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.75",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298117",
      "name": "Recommendation PA166298117",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060719,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥6.0",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298064",
      "name": "Recommendation PA166298064",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060666,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298174",
      "name": "Recommendation PA166298174",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060776,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.0",
        "CYP2C19": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298108",
      "name": "Recommendation PA166298108",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060710,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.25",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298055",
      "name": "Recommendation PA166298055",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060657,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.5",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301423",
      "name": "Recommendation Annotation PA166301423",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452095762,
        "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x≥3</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x≥3</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x≥3</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x≥3</strong> or <strong>*2x2 versus *2x≥3</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x≥3</td>\n<td>Increased</td>\n<td>≥3</td>\n<td></td>\n<td></td>\n<td>≥3</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "xN combinations",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298042",
      "name": "Recommendation PA166298042",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060644,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298152",
      "name": "Recommendation PA166298152",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060754,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.5",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298029",
      "name": "Recommendation PA166298029",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060631,
        "html": "<p>Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.25",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298113",
      "name": "Recommendation PA166298113",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060715,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.5",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298016",
      "name": "Recommendation PA166298016",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060618,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298060",
      "name": "Recommendation PA166298060",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060662,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "3.0",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298170",
      "name": "Recommendation PA166298170",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060772,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "1.0",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298126",
      "name": "Recommendation PA166298126",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060728,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.25",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298007",
      "name": "Recommendation PA166298007",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060609,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.5",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298099",
      "name": "Recommendation PA166298099",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060701,
        "html": "<p>Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.0",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298051",
      "name": "Recommendation PA166298051",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060653,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.75",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298183",
      "name": "Recommendation PA166298183",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060785,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.75",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298139",
      "name": "Recommendation PA166298139",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060741,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "No Result",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297996",
      "name": "Recommendation PA166297996",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060598,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.75",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298086",
      "name": "Recommendation PA166298086",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060688,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.5",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297983",
      "name": "Recommendation PA166297983",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060585,
        "html": "<p>Initiate therapy with recommended starting dose.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.5",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298104",
      "name": "Recommendation PA166298104",
      "population": "general",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060706,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.25",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298037",
      "name": "Recommendation PA166298037",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060639,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.75",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298081",
      "name": "Recommendation PA166298081",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060683,
        "html": "<p>Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.5",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298169",
      "name": "Recommendation PA166298169",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060771,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.75",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298121",
      "name": "Recommendation PA166298121",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060723,
        "html": "<p>Avoid imipramine use. If a imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.0",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298024",
      "name": "Recommendation PA166298024",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060626,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Greatly reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.0",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298134",
      "name": "Recommendation PA166298134",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060736,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥4.0",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298015",
      "name": "Recommendation PA166298015",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060617,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298147",
      "name": "Recommendation PA166298147",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060749,
        "html": "<p>Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "1.5",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297988",
      "name": "Recommendation PA166297988",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060590,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "3.0",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298002",
      "name": "Recommendation PA166298002",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060604,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.25",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298094",
      "name": "Recommendation PA166298094",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060696,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.75",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298112",
      "name": "Recommendation PA166298112",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060714,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.25",
        "CYP2C19": "Indeterminate"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166301405",
      "name": "Recommendation Annotation PA166301405",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452095744,
        "html": "<p>xN is not a valid input for CYP2D6 copy number alleles. Please select a copy number representation as outlined below.</p>\n<table class=\"table\">\n<thead>\n<tr>\n<th>xN Allele</th>\n<th>Possible selection</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>*1xN</td>\n<td>*1x2 or *1x≥3</td>\n</tr>\n<tr>\n<td>*2xN</td>\n<td>*2x2 or *2x≥3</td>\n</tr>\n<tr>\n<td>*3xN</td>\n<td>*3x2</td>\n</tr>\n<tr>\n<td>*4xN</td>\n<td>*4x2 or *4x≥3</td>\n</tr>\n<tr>\n<td>*6xN</td>\n<td>*6x2</td>\n</tr>\n<tr>\n<td>*35xN</td>\n<td>*35x2</td>\n</tr>\n<tr>\n<td>*36xN</td>\n<td>*36x2</td>\n</tr>\n<tr>\n<td>*43xN</td>\n<td>*43x2</td>\n</tr>\n<tr>\n<td>*45xN</td>\n<td>*45x2</td>\n</tr>\n</tbody>\n</table>\n<ul>\n<li>For normal function alleles (*1 and *2) selecting <strong>*1x2 versus *1x≥3</strong> or <strong>*2x2 versus *2x≥3</strong> will affect the resulting CYP2D6 phenotype.</li>\n<li>CPIC CYP2D6 ultrarapid metabolizer phenotype is assigned an activity score (AS) of &gt;2.25.</li>\n<li>DPWG CYP2D6 ultrarapid metabolizer phenotype is assigned an AS of &gt;2.5.</li>\n</ul>\n<table class=\"table\">\n<thead>\n<tr>\n<th>Guideline</th>\n<th>CNV Allele</th>\n<th>Function</th>\n<th>Activity<br/>value</th>\n<th>Other Allele<br/>Function</th>\n<th>Activity<br/>value</th>\n<th>CYP2D6 AS</th>\n<th>Phenotype</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>No function</td>\n<td>0</td>\n<td>2</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.25</td>\n<td>2.25</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Decreased function</td>\n<td>0.5</td>\n<td>2.5</td>\n<td>Normal metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x2</td>\n<td>Increased</td>\n<td>2</td>\n<td>Normal function</td>\n<td>1.0</td>\n<td>3.0</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n<tr>\n<td>CPIC or DPWG</td>\n<td>*1x≥3</td>\n<td>Increased</td>\n<td>≥3</td>\n<td></td>\n<td></td>\n<td>≥3</td>\n<td>Ultrarapid metabolizer</td>\n</tr>\n</tbody>\n</table>\n"
      },
      "implications": [],
      "lookupKey": {
        "CYP2D6": "xN combinations",
        "CYP2C19": "No Result"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298033",
      "name": "Recommendation PA166298033",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060635,
        "html": "<p>Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Normal metabolism of TCAs"
      ],
      "lookupKey": {
        "CYP2D6": "2.25",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297979",
      "name": "Recommendation PA166297979",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060581,
        "html": "<p>Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations for conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.75",
        "CYP2C19": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298165",
      "name": "Recommendation PA166298165",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060767,
        "html": "<p>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "No Result",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298068",
      "name": "Recommendation PA166298068",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060670,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.75",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298020",
      "name": "Recommendation PA166298020",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060622,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥5.0",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298130",
      "name": "Recommendation PA166298130",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060732,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Reduced metabolism of tertiary amines compared to normal metabolizers",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "4.0",
        "CYP2C19": "Likely Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298178",
      "name": "Recommendation PA166298178",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060780,
        "html": "<p>Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n"
      },
      "implications": [
        "CYP2C19: n/a",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "4.0",
        "CYP2C19": "No Result"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298059",
      "name": "Recommendation PA166298059",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060661,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.5",
        "CYP2C19": "Rapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298011",
      "name": "Recommendation PA166298011",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060613,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.</p>\n"
      },
      "implications": [
        "CYP2C19: Normal metabolism of tertiary amines",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "2.5",
        "CYP2C19": "Normal Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298143",
      "name": "Recommendation PA166298143",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060745,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Reduced metabolism of TCAs to less active compounds compared to normal metabolizers; Higher plasma concentrations of active drug will increase the probability of side effects"
      ],
      "lookupKey": {
        "CYP2D6": "0.5",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298046",
      "name": "Recommendation PA166298046",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060648,
        "html": "<p>Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Patients may receive an initial low dose of a tricyclic, which is then increased over several days to the recommended steady-state dose. The starting dose in this guideline refers to the recommended steady-state dose.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: n/a"
      ],
      "lookupKey": {
        "CYP2D6": "n/a",
        "CYP2C19": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298090",
      "name": "Recommendation PA166298090",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060692,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate, or poor metabolism in combination with CYP2C19 ultrarapid, intermediate, or poor metabolism is strongly recommended</p>\n"
      },
      "implications": [
        "CYP2C19: Increased metabolism of tertiary amines compared to normal metabolizers; Greater conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "≥3.0",
        "CYP2C19": "Ultrarapid Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166298156",
      "name": "Recommendation PA166298156",
      "population": "general",
      "classification": {
        "term": "Optional",
        "termId": "guidelineStrength:981565059"
      },
      "relatedChemicals": [
        {
          "id": "PA449969",
          "name": "imipramine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060758,
        "html": "<p>Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>Dosing recommendations only apply to higher initial doses of TCAs for treatment of conditions such as depression. See other considerations for dosing recommendations\nfor conditions where lower initial doses are used, such as neuropathic pain. Utilizing therapeutic drug monitoring if a tricyclic is prescribed to a patient with CYP2D6 ultrarapid, intermediate or poor metabolism in combination with CYP2C19 ultrarapid, intermediate or poor metabolism is strongly recommended.</p>\n"
      },
      "implications": [
        "CYP2C19: Greatly reduced metabolism of tertiary amines compared to normal metabolizers; Decreased conversion of tertiary amines to secondary amines may affect response or side effects",
        "CYP2D6: Increased metabolism of TCAs to less active compounds compared to normal metabolizers; Lower plasma concentrations of active drug will increase probability of pharmacotherapy failure"
      ],
      "lookupKey": {
        "CYP2D6": "4.0",
        "CYP2C19": "Likely Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "27997040",
      "title": "Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.",
      "authors": [
        "Hicks J K",
        "Sangkuhl K",
        "Swen J J",
        "Ellingrod V L",
        "Müller D J",
        "Shimoda K",
        "Bishop J R",
        "Kharasch E D",
        "Skaar T C",
        "Gaedigk A",
        "Dunnenberger H M",
        "Klein T E",
        "Caudle K E",
        "Stingl J C"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2017
    },
    {
      "pmid": "23486447",
      "title": "Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants.",
      "authors": [
        "Hicks J K",
        "Swen J J",
        "Thorn C F",
        "Sangkuhl K",
        "Kharasch E D",
        "Ellingrod V L",
        "Skaar T C",
        "Müller D J",
        "Gaedigk A",
        "Stingl J C",
        "Clinical Pharmacogenetics Implementation Consortium"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2013
    }
  ],
  "version": "2023-12-19-10-38"
}